These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 38058292)
1. Pharmacokinetic evaluation of sofosbuvir/velpatasvir for the treatment of Chronic Hepatitis C in pediatrics aged 3 and older. Tuan J; Okoli A; Ogbuagu O Expert Opin Drug Metab Toxicol; 2023 Dec; 19(12):881-888. PubMed ID: 38058292 [TBL] [Abstract][Full Text] [Related]
2. Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection. Indolfi G; Kelly D; Nebbia G; Iorio R; Mania A; Giacomet V; Szenborn L; Shao J; Sang Yue M; Hsueh CH; Parhy B; Kersey K; Mangia A; Pawlowska M; Bansal S Hepatology; 2022 Aug; 76(2):445-455. PubMed ID: 35112372 [TBL] [Abstract][Full Text] [Related]
3. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. Jonas MM; Romero R; Rosenthal P; Lin CH; Verucchi G; Wen J; Balistreri WF; Whitworth S; Bansal S; Leung DH; Narkewicz MR; Gonzalez-Peralta RP; Mangia A; Karnsakul W; Rao GS; Shao J; de Jong J; Parhy B; Osinusi A; Kersey K; Murray KF; Sokal EM; Schwarz KB J Pediatr Gastroenterol Nutr; 2024 Jun; 78(6):1342-1354. PubMed ID: 38644678 [TBL] [Abstract][Full Text] [Related]
4. Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China. Zhou Y; Liang M; Li Y; Chen X; Yang J; Bai H; Long Y; Zhang X; Lin C BMC Gastroenterol; 2024 Feb; 24(1):73. PubMed ID: 38355447 [TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. Borgia SM; Dearden J; Yoshida EM; Shafran SD; Brown A; Ben-Ari Z; Cramp ME; Cooper C; Foxton M; Rodriguez CF; Esteban R; Hyland R; Lu S; Kirby BJ; Meng A; Markova S; Dvory-Sobol H; Osinusi AO; Bruck R; Ampuero J; Ryder SD; Agarwal K; Fox R; Shaw D; Haider S; Willems B; Lurie Y; Calleja JL; Gane EJ J Hepatol; 2019 Oct; 71(4):660-665. PubMed ID: 31195062 [TBL] [Abstract][Full Text] [Related]
6. ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings. Indolfi G; Gonzalez-Peralta RP; Jonas MM; Sayed MH; Fischler B; Sokal E; Wirth S; Nicastro E; J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):957-972. PubMed ID: 38369891 [TBL] [Abstract][Full Text] [Related]
7. Deferred treatment with a fixed-dose combination of sofosbuvir-velpatasvir for chronic hepatitis C virus genotype 1, 2, 4 and 6 infection. Asselah T; Shafran SD; Bourgeois S; Lai CL; Mathurin P; Willems B; Nguyen MH; Davis MN; Huang KC; Svarovskaia E; Osinusi A; McNally J; Brainard DM; Shaikh OS; Tran TT J Viral Hepat; 2019 Oct; 26(10):1229-1232. PubMed ID: 31216086 [TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. Chahine EB; Kelley D; Childs-Kean LM Ann Pharmacother; 2018 Apr; 52(4):352-363. PubMed ID: 29115151 [TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. Foster GR; Afdhal N; Roberts SK; Bräu N; Gane EJ; Pianko S; Lawitz E; Thompson A; Shiffman ML; Cooper C; Towner WJ; Conway B; Ruane P; Bourlière M; Asselah T; Berg T; Zeuzem S; Rosenberg W; Agarwal K; Stedman CA; Mo H; Dvory-Sobol H; Han L; Wang J; McNally J; Osinusi A; Brainard DM; McHutchison JG; Mazzotta F; Tran TT; Gordon SC; Patel K; Reau N; Mangia A; Sulkowski M; ; N Engl J Med; 2015 Dec; 373(27):2608-17. PubMed ID: 26575258 [TBL] [Abstract][Full Text] [Related]
20. Sofosbuvir/velpatasvir: a pangenotypic drug to simplify HCV therapy. Lee R; Kottilil S; Wilson E Hepatol Int; 2017 Mar; 11(2):161-170. PubMed ID: 27928718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]